The Medical Letter on Drugs and Therapeutics
Teduglutide Injection (Gattex) for Short Bowel Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on parenteral support.

SHORT BOWEL SYNDROME — SBS is a rare disorder caused by a significant loss of functioning small bowel. In young children, SBS is often caused by congenital defects. Surgical resection for disorders such as Crohn’s disease is the most common cause in adults. The length of the small intestine in normal adults ranges from 300-850 cm; patients with SBS typically have <200 cm of small bowel remaining and those with <100 cm remaining are likely to have intestinal failure. Patients with SBS-associated intestinal failure are unable to absorb sufficient quantities of protein, calories, fluids, electrolytes and micronutrients and often experience diarrhea, weight loss, malnutrition ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Teduglutide Injection (Gattex) for Short Bowel Syndrome
Article code: 1414b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian